POPULATION SURVIVAL
Prostate Published source values Male · All Ages · All Stages · All Races / Ethnicities · Source code 66 (label not supplied)
Source SEER
Table Conditional Survival
Data submission November 2025 submission
Application release 2026-04-22
Updated June 22, 2026
Retrieved 2026-09-10 This package stores a diagnosis-period code and no label for it. No calendar range is added.
Relative survival over the next five years for Prostate, conditional on time already survived. Source table: SEER Conditional Survival. Already survived Relative survival (%) Lower CI Upper CI Standard error Source count Already survived 0 years 98.153595 98.086232 98.218609 0.033763 1768233 Already survived 1 years 98.796988 98.725114 98.864833 0.035623 1691667 Already survived 3 years 99.557020 99.469802 99.629916 0.040628 1408229 Already survived 5 years 99.827482 99.704779 99.899212 0.047300 1178295
Open the SEER source
5-Year Survival Conditional Survival Recent Trends Long-Term Trends Cancer source group Acute Lymphocytic Leukemia (ALL) Acute Monocytic Leukemia (AML-M5) Acute Myeloid Leukemia (AML) Adenocarcinoma of the Esophagus Adenocarcinoma of the Lung and Bronchus All Cancer Sites Combined Anus, Anal Canal & Anorectum Bones and Joints Brain and Other Nervous System Breast Cervix Uteri Chronic Lymphocytic Leukemia (CLL) Chronic Myeloid Leukemia (CML) Chronic Myelomonocytic Leukemia (CMML) Chronic myeloproliferative disorders (CMD) Colon (including Appendix) Colon and Rectum (excluding Appendix) Colon and Rectum (including Appendix) Corpus and Uterus, NOS Diffuse Astrocytoma and Anaplastic Astrocytoma of the Brain and ONS Embryonal Tumors of the Brain and ONS Esophagus Eye and Orbit Floor of Mouth Follicular Subtype of the Thyroid Gallbladder Glioblastoma of the Brain and ONS Gum & other mouth Hodgkin Lymphoma Kaposi Sarcoma Kidney Kidney and Renal Pelvis Large Cell Carcinoma of the Lung and Bronchus Larynx Leukemia Lip Liver and Intrahepatic Bile Duct Lung and Bronchus Melanoma of the Skin Meningioma of the Brain and ONS Mesothelioma Myelodysplastic syndromes (MDS) Myeloma Non-Hodgkin Lymphoma Oral Cavity and Pharynx Oropharynx & Tonsil Other Glioma of the Brain and ONS Ovary Pancreas Papillary Subtype of the Thyroid Prostate Rectum Renal Pelvis Salivary Gland Small cell carcinoma of the Lung and Bronchus Small Intestine Soft Tissue including Heart Squamous Cell Carcinoma of the Esophagus Squamous Cell Carcinoma of the Lung and Bronchus Stomach Testis Thyroid Tongue Urinary Bladder (Invasive & In Situ) Vagina Vulva
Filters stay in your browser. Some combinations have no estimate.
SEER · SOURCE POPULATIONS
Survival over the next five years Each estimate covers the five years following the stated point, among people who have already survived to that point. It is not survival measured from diagnosis.
Loading the exact source populations…
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Relative survival compares cancer populations with the general population. It is not the percentage of people alive, a treatment effect, or a personal forecast. Diagnosis-period dates were not labeled in the recovered package; see the source notes below.